AlphAIAlphAI — Financial news for AI agents
tradingview.comNOV 41 min read$HRMY

Harmony Biosciences (HRMY) Q3 WAKIX Revenue Rose 12% to $268.9M

Harmony Biosciences (HRMY) reported Q3 2026 WAKIX revenue of $268.9M, a 12% increase from the prior year, and maintained its 2026 guidance of $1.0B–$1.04B. Net income was $48.2M, down from $50.9M. The company expects Q1 2027 Phase 1b data for BP-205 and mid-2027 Phase 2 starts.

Original reporting
tradingview.com
Published Nov 4, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Harmony Biosciences (HRMY) Q3 WAKIX Revenue Rose 12% to $268.9M — source image
Source · tradingview.com
Decision brief

The 30-second read

$HRMYNeutralMed
01

Why it matters

The earnings release provides the first detailed financial update for Q3 2026, setting expectations for 2026 guidance and future pipeline milestones.

02

Market read

First earnings report of the quarter; provides new data for traders evaluating small‑cap biotech exposure.

03

What to watch

The upcoming Phase 1b data for BP-205 in Q1 2027 could be a catalyst that outweighs short‑term guidance concerns.

Relevance 7/10Novelty 7/10Timing: today

Background

Harmony Biosciences is a specialty biotech with a commercial product (WAKIX) and an early‑stage pipeline (BP-205).

Company-level read

Ticker impact

$HRMYNeutralHigh confidence
Context

Harmony Biosciences reported Q3 2026 revenue of $268.9M, up 12%, and reiterated 2026 guidance of $1.0B–$1.04B.

Expected impact

modest downside as investors price in flat guidance and slight earnings miss

Evidence & confidence

Revenue growth is positive, but unchanged guidance and a dip in net income suggest limited upside; market may react cautiously.

Market effects

Sector

Biotech sector may see modest impact as the report highlights a commercial franchise with early‑stage pipeline.

Regional

U.S. biotech investors may adjust exposure to small‑cap growth stocks.

Global

Limited; primarily relevant to U.S. biotech and specialty pharma investors.

Counterpoint

What could challenge this read

If investors focus on the 12% revenue growth and upcoming BP-205 data, the stock could rally on upside potential.

Key entities

  • company
    Harmony Biosciences

    Biotech firm reporting Q3 2026 results.

Read at source← All news

StoryHarmony Biosciences posts Q3 revenue growth but EPS miss, shares slide

Also covered by

2 outlets

Related articles

NOV 4
$HRMYMed

Harmony Biosciences 3Q 2026: Revenue $268.92M, Net income $48.2M, EPS $0.81— 10-Q Summary

Harmony Biosciences reported Q3 2026 revenue of $268.92M, up 12.3% YoY, but net income fell 5.2% to $48.2M and EPS declined 6.9% to $0.81. WAKIX revenue grew 12.3% in the quarter, driven by higher shipments and a price increase. The FDA accepted the Pitolisant GR NDA for review, with a target PDUFA date of April 1, 2027. Phase 3 trials for EPX-100 and Pitolisant HD are ongoing, with results expected in 2027. The company also began a Phase 1b study of BP-205.

tradingview.com1 min
NOV 4
$HRMYMedAI 8/10

Harmony Biosciences Reports Q3 Financial Results

Harmony Biosciences Holdings, Inc. (HRMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. ‌ Exhibit 99.1 Harmony Biosciences Reports Q3 Financial Results On Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile ​ WAKIX ® Net Revenue in Q3 of $2

SEC EDGAR 8-K2 min